Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Peguero JA"'
Autor:
Lim HY; Department of Medicine, Division of Hematology-Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea., Heo J; Department of Internal Medicine, College of Medicine, Pusan National University and Medical Research Institute, Busan, Republic of Korea., Peguero JA; Oncology Consultants, Houston, Texas, USA., Ryoo BY; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea., Decaens T; University Grenoble Alpes/Hepato-Gastroenterology and Digestive Oncology Department, CHU Grenoble Alpes/Institute for Advanced Biosciences, CNRS UMR 5309-INSERM U1209, Grenoble, France., Barlesi F; Department of Medical Oncology, Paris-Saclay University, Gustave Roussy Cancer Campus, Villejuif, France., Moehler MH; Johannes Gutenberg-University Clinic, Mainz, Germany., Jehl G; The healthcare business of Merck KGaA, Darmstadt, Germany., Eggleton SP; Merck Serono Ltd., Feltham, UK, an affiliate of Merck KGaA, Darmstadt, Germany., Bajars M; The healthcare business of Merck KGaA, Darmstadt, Germany., Gulley JL; Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Publikováno v:
Hepatology (Baltimore, Md.) [Hepatology] 2024 Aug 13. Date of Electronic Publication: 2024 Aug 13.
Autor:
Yaeger R; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York., Uboha NV; Division of Hematology and Oncology, Department of Medicine, University of Wisconsin, Madison, Wisconsin., Pelster MS; Sarah Cannon Research Institute, Tennessee Oncology, Nashville, Tennessee., Bekaii-Saab TS; Department of Medical Oncology and Hematology, Mayo Clinic, Scottsdale, Arizona., Barve M; Mary Crowley Cancer Research Center, Dallas, Texas., Saltzman J; Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, Ohio., Sabari JK; Division of Medical Oncology, Perlmutter Cancer Center, New York University Langone Health, New York, New York., Peguero JA; Department of Research, Oncology Consultants PA, Houston, Texas., Paulson AS; Department of Medical Oncology, Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas, Texas., Jänne PA; Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts., Cruz-Correa M; PanOncology Trials, San Juan, Puerto Rico., Anderes K; Mirati Therapeutics, a wholly owned subsidiary of Bristol Myers Squibb Company, San Diego, California., Velastegui K; Mirati Therapeutics, a wholly owned subsidiary of Bristol Myers Squibb Company, San Diego, California., Yan X; Mirati Therapeutics, a wholly owned subsidiary of Bristol Myers Squibb Company, San Diego, California., Der-Torossian H; Mirati Therapeutics, a wholly owned subsidiary of Bristol Myers Squibb Company, San Diego, California., Klempner SJ; Division of Hematology-Oncology, Massachusetts General Cancer Center, Boston, Massachusetts., Kopetz SE; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Publikováno v:
Cancer discovery [Cancer Discov] 2024 Jun 03; Vol. 14 (6), pp. 982-993.
Autor:
Damodaran S; Department of Breast Medical Oncology, The University of Texas, MD Anderson Cancer Center, Houston. Electronic address: SDamodaran@mdanderson.org., O'Sullivan CC; Department of Oncology, Mayo Clinic, Rochester., Elkhanany A; Baylor College of Medicine, Duncan Cancer Center - Breast, Houston., Anderson IC; Providence Medical Group, Santa Rosa., Barve M; Mary Crowley Cancer Research, Dallas., Blau S; Oncology Division, Northwest Medical Specialties, PPLC, Puyallup., Cherian MA; Division of Medical Oncology, The Ohio State University Comprehensive Cancer Center, Columbus., Peguero JA; Department of Research, Oncology Consultants PA, Houston., Goetz MP; Department of Oncology, Mayo Clinic, Rochester., Plourde PV; Sermonix Pharmaceuticals, Columbus., Portman DJ; Sermonix Pharmaceuticals, Columbus., Moore HCF; Cleveland Clinic Taussig Cancer Institute, Cleveland, USA.
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2023 Dec; Vol. 34 (12), pp. 1131-1140.
Autor:
Blau S; Rainier Hematology Oncology/Northwest Medical Specialties, Seattle, WA., Peguero JA; Department of Research, Oncology Consultants PA, Houston, TX., Moore HCF; Cleveland Clinic, Cleveland, OH., Anderson IC; Providence Medical Group, Santa Rosa, CA., Barve MA; Mary Crowley Cancer Research, Dallas, TX., Cherian MA; The Ohio State University Arthur G. James Cancer Hospital, Columbus, OH., Elkhanany A; University of Alabama at Birmingham, Birmingham, AL., O'Sullivan CC; Mayo Clinic Cancer Center, Rochester, MN., Moreno-Aspitia A; Mayo Clinic Cancer Center, Jacksonville, FL., Plourde P; Sermonix Pharmaceuticals, Columbus, OH., Gleich LL; Medpace, Cincinnati, OH., Riesen K; Medpace, Cincinnati, OH., Ezzati R; Medpace, Cincinnati, OH., Degele M; Tempus Labs, Chicago, IL., Shulman M; Tempus Labs, Chicago, IL., Stempf SD; Tempus Labs, Chicago, IL., Sachse L; Tempus Labs, Chicago, IL., Iyer AA; Tempus Labs, Chicago, IL., Damodaran S; The University of Texas MD Anderson Cancer Center, Houston, TX., Cooney MM; Tempus Labs, Chicago, IL.
Publikováno v:
JCO clinical cancer informatics [JCO Clin Cancer Inform] 2023 Jun; Vol. 7, pp. e2200164.
Autor:
Holmes JP; St. Joseph Health Cancer Center, Santa Rosa, California (Dr Holmes); Oncology Consultants PA, Department of Research, Houston, Texas (Dr Peguero); Baylor Scott & White Medical Center, Temple, Texas (Dr Garland); and TerSera Therapeutics, Deerfield, Illinois (Ms North and Drs Young, Brent, and Joseph-Ridge).; Jarrod P. Holmes, MD, FACP, is a hematologist/oncologist and associate medical director of oncology for Northern California, Providence Medical Group, in Santa Rosa, California.; Julio A. Peguero, MD, is board certified in internal medicine and medical oncology and the director of research at Oncology Consultants in Houston, Texas.; R. Campbell Garland, DO, is a hematologist/oncologist at Baylor Scott & White Medical Center based in Central Texas.; Janine North, BS, is executive director of clinical development at TerSera Therapeutics, in Deerfield, Illinois.; Stacia Young, PharmD, BCOP, MBA, is director of oncology medical science liaisons at TerSera Therapeutics.; Lonnie D. Brent, PharmD, is vice president of medical affairs at TerSera Therapeutics.; Nancy Joseph-Ridge, MD, is executive vice president of research and development and chief medical officer at TerSera Therapeutics., Peguero JA; St. Joseph Health Cancer Center, Santa Rosa, California (Dr Holmes); Oncology Consultants PA, Department of Research, Houston, Texas (Dr Peguero); Baylor Scott & White Medical Center, Temple, Texas (Dr Garland); and TerSera Therapeutics, Deerfield, Illinois (Ms North and Drs Young, Brent, and Joseph-Ridge).; Jarrod P. Holmes, MD, FACP, is a hematologist/oncologist and associate medical director of oncology for Northern California, Providence Medical Group, in Santa Rosa, California.; Julio A. Peguero, MD, is board certified in internal medicine and medical oncology and the director of research at Oncology Consultants in Houston, Texas.; R. Campbell Garland, DO, is a hematologist/oncologist at Baylor Scott & White Medical Center based in Central Texas.; Janine North, BS, is executive director of clinical development at TerSera Therapeutics, in Deerfield, Illinois.; Stacia Young, PharmD, BCOP, MBA, is director of oncology medical science liaisons at TerSera Therapeutics.; Lonnie D. Brent, PharmD, is vice president of medical affairs at TerSera Therapeutics.; Nancy Joseph-Ridge, MD, is executive vice president of research and development and chief medical officer at TerSera Therapeutics., Garland RC; St. Joseph Health Cancer Center, Santa Rosa, California (Dr Holmes); Oncology Consultants PA, Department of Research, Houston, Texas (Dr Peguero); Baylor Scott & White Medical Center, Temple, Texas (Dr Garland); and TerSera Therapeutics, Deerfield, Illinois (Ms North and Drs Young, Brent, and Joseph-Ridge).; Jarrod P. Holmes, MD, FACP, is a hematologist/oncologist and associate medical director of oncology for Northern California, Providence Medical Group, in Santa Rosa, California.; Julio A. Peguero, MD, is board certified in internal medicine and medical oncology and the director of research at Oncology Consultants in Houston, Texas.; R. Campbell Garland, DO, is a hematologist/oncologist at Baylor Scott & White Medical Center based in Central Texas.; Janine North, BS, is executive director of clinical development at TerSera Therapeutics, in Deerfield, Illinois.; Stacia Young, PharmD, BCOP, MBA, is director of oncology medical science liaisons at TerSera Therapeutics.; Lonnie D. Brent, PharmD, is vice president of medical affairs at TerSera Therapeutics.; Nancy Joseph-Ridge, MD, is executive vice president of research and development and chief medical officer at TerSera Therapeutics., North J; St. Joseph Health Cancer Center, Santa Rosa, California (Dr Holmes); Oncology Consultants PA, Department of Research, Houston, Texas (Dr Peguero); Baylor Scott & White Medical Center, Temple, Texas (Dr Garland); and TerSera Therapeutics, Deerfield, Illinois (Ms North and Drs Young, Brent, and Joseph-Ridge).; Jarrod P. Holmes, MD, FACP, is a hematologist/oncologist and associate medical director of oncology for Northern California, Providence Medical Group, in Santa Rosa, California.; Julio A. Peguero, MD, is board certified in internal medicine and medical oncology and the director of research at Oncology Consultants in Houston, Texas.; R. Campbell Garland, DO, is a hematologist/oncologist at Baylor Scott & White Medical Center based in Central Texas.; Janine North, BS, is executive director of clinical development at TerSera Therapeutics, in Deerfield, Illinois.; Stacia Young, PharmD, BCOP, MBA, is director of oncology medical science liaisons at TerSera Therapeutics.; Lonnie D. Brent, PharmD, is vice president of medical affairs at TerSera Therapeutics.; Nancy Joseph-Ridge, MD, is executive vice president of research and development and chief medical officer at TerSera Therapeutics., Young S; St. Joseph Health Cancer Center, Santa Rosa, California (Dr Holmes); Oncology Consultants PA, Department of Research, Houston, Texas (Dr Peguero); Baylor Scott & White Medical Center, Temple, Texas (Dr Garland); and TerSera Therapeutics, Deerfield, Illinois (Ms North and Drs Young, Brent, and Joseph-Ridge).; Jarrod P. Holmes, MD, FACP, is a hematologist/oncologist and associate medical director of oncology for Northern California, Providence Medical Group, in Santa Rosa, California.; Julio A. Peguero, MD, is board certified in internal medicine and medical oncology and the director of research at Oncology Consultants in Houston, Texas.; R. Campbell Garland, DO, is a hematologist/oncologist at Baylor Scott & White Medical Center based in Central Texas.; Janine North, BS, is executive director of clinical development at TerSera Therapeutics, in Deerfield, Illinois.; Stacia Young, PharmD, BCOP, MBA, is director of oncology medical science liaisons at TerSera Therapeutics.; Lonnie D. Brent, PharmD, is vice president of medical affairs at TerSera Therapeutics.; Nancy Joseph-Ridge, MD, is executive vice president of research and development and chief medical officer at TerSera Therapeutics., Brent LD; St. Joseph Health Cancer Center, Santa Rosa, California (Dr Holmes); Oncology Consultants PA, Department of Research, Houston, Texas (Dr Peguero); Baylor Scott & White Medical Center, Temple, Texas (Dr Garland); and TerSera Therapeutics, Deerfield, Illinois (Ms North and Drs Young, Brent, and Joseph-Ridge).; Jarrod P. Holmes, MD, FACP, is a hematologist/oncologist and associate medical director of oncology for Northern California, Providence Medical Group, in Santa Rosa, California.; Julio A. Peguero, MD, is board certified in internal medicine and medical oncology and the director of research at Oncology Consultants in Houston, Texas.; R. Campbell Garland, DO, is a hematologist/oncologist at Baylor Scott & White Medical Center based in Central Texas.; Janine North, BS, is executive director of clinical development at TerSera Therapeutics, in Deerfield, Illinois.; Stacia Young, PharmD, BCOP, MBA, is director of oncology medical science liaisons at TerSera Therapeutics.; Lonnie D. Brent, PharmD, is vice president of medical affairs at TerSera Therapeutics.; Nancy Joseph-Ridge, MD, is executive vice president of research and development and chief medical officer at TerSera Therapeutics., Joseph-Ridge N; St. Joseph Health Cancer Center, Santa Rosa, California (Dr Holmes); Oncology Consultants PA, Department of Research, Houston, Texas (Dr Peguero); Baylor Scott & White Medical Center, Temple, Texas (Dr Garland); and TerSera Therapeutics, Deerfield, Illinois (Ms North and Drs Young, Brent, and Joseph-Ridge).; Jarrod P. Holmes, MD, FACP, is a hematologist/oncologist and associate medical director of oncology for Northern California, Providence Medical Group, in Santa Rosa, California.; Julio A. Peguero, MD, is board certified in internal medicine and medical oncology and the director of research at Oncology Consultants in Houston, Texas.; R. Campbell Garland, DO, is a hematologist/oncologist at Baylor Scott & White Medical Center based in Central Texas.; Janine North, BS, is executive director of clinical development at TerSera Therapeutics, in Deerfield, Illinois.; Stacia Young, PharmD, BCOP, MBA, is director of oncology medical science liaisons at TerSera Therapeutics.; Lonnie D. Brent, PharmD, is vice president of medical affairs at TerSera Therapeutics.; Nancy Joseph-Ridge, MD, is executive vice president of research and development and chief medical officer at TerSera Therapeutics.
Publikováno v:
Journal of infusion nursing : the official publication of the Infusion Nurses Society [J Infus Nurs] 2021 Nov-Dec 01; Vol. 44 (6), pp. 315-322.
Autor:
Rugo HS; University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA. Electronic address: hope.rugo@ucsf.edu., Seneviratne L; Los Angeles Cancer Network, Los Angeles, CA, USA., Beck JT; Highlands Oncology Group, Fayetteville, AR., Glaspy JA; University of California Los Angeles School of Medicine, Los Angeles, CA, USA., Peguero JA; Oncology Consultants PA, Department of Research, Houston, TX, USA., Pluard TJ; St Luke's Cancer Institute, Kansas City, MO, USA., Dhillon N; Cancer Treatment Centers of America, Atlanta, GA, USA., Hwang LC; Kaiser Permanente Mid-Atlantic States, Gaithersburg, MD, USA., Nangia C; UC Irvine Health Chao Family Comprehensive Cancer Center, Orange, CA, USA., Mayer IA; Vanderbilt-Ingram Comprehensive Cancer Center, Nashville, TN, USA., Meiller TF; Oncology and Diagnostic Sciences, Dental School and The Marlene and Stewart Greenebaum Comprehensive Cancer Center University of Maryland Medical Center, Baltimore, MD, USA., Chambers MS; The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Sweetman RW; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA., Sabo JR; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA., Litton JK; The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Publikováno v:
The Lancet. Oncology [Lancet Oncol] 2017 May; Vol. 18 (5), pp. 654-662. Date of Electronic Publication: 2017 Mar 15.